Publications by authors named "R N Formica"
Face transplantation has emerged as reconstructive option for the most challenging facial deformities. A comprehensive analysis of functional outcomes, medical complications, incidence of malignancy, and chronic rejection in face transplantation recipients over an extended follow-up period has not yet been published leaving a notable gap in the literature. We retrospectively collected data of morbidity, rejection, vasculopathy, metabolic side effects, as well as functional outcome of sensory return, facial motor function, and speech from 9 patients who underwent face transplantation at Brigham and Women's Hospital between 2009 and 2020.
View Article and Find Full Text PDFTo date, little is known about the mechanisms of rejection in vascularized composite allotransplantation, particularly for antibody mediated rejection. Additionally, no clear guidelines exist for the diagnosis and management of antibody-mediated rejection in vascularized composite allotransplantation. A systematic review of electronic databases (Embase and PubMed) was conducted to evaluate the relationship of donor specific antibodies and C4d deposition in correlation with cellular rejection following hand and face transplantation reported by centers between 1998 and July 2023.
View Article and Find Full Text PDFBackground: Recipients of Vascularized Composite Allotransplants require effective immunosuppressive therapy to prevent graft rejection. This systematic review summarizes the current body of literature on immunosuppressive regimens used in face and hand transplants while summarizing their outcome in terms of rejection, renal failure, and infections.
Methods: A systematic search of electronic databases was conducted to identify relevant studies from 1998 until July 1st, 2023.
Article Synopsis
- LCPT (Envarsus XR®) is an extended-release tacrolimus used in kidney transplants, but there's a lack of clear guidelines on its dosing and use in new patients or those switching from other forms.
- A group of 12 experts used the Delphi method to create and refine consensus statements on LCPT use, achieving significant agreement on 18 out of 23 generated statements after two rounds of feedback.
- Key findings included that LCPT is recommended as a first-line option for new patients, especially African Americans and rapid metabolizers, and that conversion to LCPT is effective for mitigating neurological side effects from immediate-release tacrolimus.